TX-MAVENIR
8.10.2019 14:02:05 CEST | Business Wire | Press release
Mavenir, the industry’s only end-to-end, cloud-native Network Software Provider, today announced its Mobile Business Fabric™, a dynamic and fluid business communications framework designed to meet the evolving digital needs of businesses as mobility becomes a primary driver and customers demand change.
Mavenir’s Mobile Business Fabric™ consists of a portfolio of integrated business solutions with a focus on enabling deskless, mobile workers for businesses of all sizes—from SMBs to large enterprises. This portfolio integrates mobile voice, mobile video, rich communication services (RCS) and SMS messaging, voicemail, interactive voice response (IVR), chatbots, SpamShield™ fraud management and monetization enablers into secure, carrier-grade cloud offerings.
These are combined with digital enablement capabilities for provisioning, onboarding, and invoicing businesses via an intuitive, omnichannel interface. This embedded functionality avoids long, complex and costly integrations with the existing legacy business support systems (BSS) of the service provider or channel partner, accelerating time-to-market and time-to-revenue.
Mavenir’s Mobile Business Fabric solutions are currently deployed and under deployment in several Tier 1 MNOs in the US, UK, Spain, Germany, India and Japan.
“Mavenir’s vision is to transform mobile network economics and accelerate the business transformation for mobile operators and channel partners,” said Guillaume Le Mener, SVP and GM, Mobile Enterprise Solutions, Mavenir. “Mobile Business Fabric is a cohesive portfolio that provides true mobile-native experiences and addresses the deskless mobile user base to generate additional revenue streams, protect their existing customer base and reduce customer churn.”
Supporting Information:
- Today, 80% of the global workforce are mobile “deskless” first line workers and the top 8 deskless industries—agriculture, education, healthcare, retail, hospitality, manufacturing, transportation and construction—employ 2.7 billion employeesi .
- Deskless mobile workers require simplified workflows leveraging their powerful mobile devices on the go.
- Today, the majority of solutions in the market have been designed for office workers and then adapted to include some limited mobility capabilities. This can lead to user frustration, particularly for emerging mobile small and medium businesses (SMBs), which have been underserved.
Mavenir’s Mobile Business Fabric flips the paradigm over with a mobile-native portfolio that doesn’t require IT administrators, hardware investments, or complex device management, while providing seamless onboarding to help accelerate time to revenue.
“As an innovative and agile Software as a Service (SaaS) solution, Mavenir’s Mobile Business Fabric portfolio enables our global partners to target the Enterprise market, as well as the underserved SMB segment,” said Marek Wasilewski, SVP, Global Enterprise Channel. “Our disruptive solutions designed for the deskless mobile workers—who typically have an I want to do it myself and I want it now mentality—simplify onboarding, remove management complexity, and, ultimately, are focused on adding positive business outcomes."
The Mobile Business Fabric portfolio comes to market with the following solutions:
- Mobile Business Messaging — RCS Business Messaging as a service that enables MNOs to address the brands’ need to communicate with customers on the mobile messaging channel—including marketing campaigns (A2P) and chatbots (P2A)—leveraging Mavenir’s RBM Partner Ecosystem to accelerate time-to-revenue.
- Mobile Business Contact — Helping businesses of all sizes to minimize the number of missed business opportunities with a white label omni-channel contact center as a service (CCaaS) designed for quick and easy access. It enables seamless omni-channel (phone, email, chat, text-message, social) interactions with customers; with fast deployment using pre-built templates and API integrations with popular tools and AI platforms.
- Mobile Business Communications and Collaboration — unified communications and collaboration as a service (UCaaS) built on mobile call control elements, that leverages mobile network quality of service (QoS) enforcement as well as RCS messaging to allow businesses to text with both internal and external users, breaking the traditional restrictions of proprietary instant messaging implementations.
The Mobile Business Fabric solutions announced are available today as a service hosted from the Mavenir cloud or deployed in the service provider’s network. Mavenir is already adapting more products and solutions into the Fabric, expected in early 2020.
To learn more, visit Mavenir's Mobile Business Fabric page.
NOTE: Mavenir will be showcasing Mobile Business Fabric with live demos at Mobile World Congress 2019 Los Angeles. To request a meeting, visit https://mavenir.com/buzz/events/mwc-la-2019
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native network software provider. Focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and Virtualized RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2019 Mavenir Systems, Inc. All Rights Reserved.
i Emergence: Rise of the Deskless Workforce , 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom